jun zhang - Infectious Diseases

Author Information

Jun Zhang is a prominent researcher in the field of infectious diseases. He is affiliated with The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics at the National Institute of Diagnostics and Vaccine Development in Infectious Diseases. He is also part of the Collaborative Innovation Center of Biologic Products and the School of Public Health at Xiamen University in Xiamen, China. His work primarily focuses on the development of vaccines and diagnostics for infectious diseases, contributing significantly to public health research.

Research Contributions

Jun Zhang has made substantial contributions to the study of infectious diseases, with a focus on vaccine development and immune response mechanisms. In 2022, he was involved in several notable studies, including the development of a rapid neutralization assay for coxsackievirus B1, the creation of a skin- and neuro-attenuated live vaccine for varicella, and the investigation of naturally acquired antibodies against SARS-CoV-2. His work also covers the structural analysis of virus capsids and the development of broad-spectrum COVID-19 vaccines. These studies highlight his commitment to advancing our understanding of virology and immunology.

Aliases

Jun Zhang is the name used in academic and research publications. There are no other significant aliases or variations of his name reported in the data.

Publication and Citation Metrics

Metric	Count
Total Papers	348
Total Citations	10,667
h-index	49

Publications:

Development of a rapid neutralization assay for the detection of neutralizing antibodies against coxsackievirus B1.

DOI: 10.1016/j.diagmicrobio.2022.115676

Year: 2022

Structures of pseudorabies virus capsids

DOI: 10.1038/s41467-022-29250-3

Year: 2022

Pre-existing maternal IgG antibodies as a protective factor against congenital cytomegalovirus infection: A mother-child prospective cohort study

DOI: 10.1016/j.ebiom.2022.103885

Year: 2022

Development of a skin- and neuro-attenuated live vaccine for varicella

DOI: 10.1038/s41467-022-28329-1

Year: 2022

The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis

DOI: 10.1080/22221751.2022.2046446

Year: 2022

Long-Term immunopersistence and safety of the Escherichia coli-produced HPV-16/18 bivalent vaccine in Chinese adolescent girls.

DOI: 10.1080/21645515.2022.2061248

Year: 2022

Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis

DOI: 10.1186/s12885-022-09413-7

Year: 2022

Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants

DOI: 10.1016/j.celrep.2022.110558

Year: 2022

A prophylactic effect of aluminium-based adjuvants against respiratory viruses via priming local innate immunity

DOI: 10.1080/22221751.2022.2050951

Year: 2022

Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine

DOI: 10.1101/2022.01.25.477789

Year: 2022

Can Targeting Metabolic Pathways Serve as a Therapeutic Strategy?

How Can We Improve Global Health Infrastructure to Combat Infectious Diseases?

How Does the CDC Educate the Public About Infectious Diseases?

How do emerging infectious diseases pose a threat?

What is Ritonavir?

What are the Global Statistics on Infectious Disease Mortality?

How Can We Support the Global Fund?

How Can HSV Be Prevented?

What Are the Challenges in Infectious Disease Epidemiology?

What are the Safety Concerns with New Therapies?

Partnered Content Networks

Relevant Topics